Latest news with #RegenerativeMedicine
Globe and Mail
5 days ago
- Business
- Globe and Mail
Collagen & Gelatin Market worth US$1,671.3 million in 2030 5.8% CAGR
"The report profiles key players such as Integra LifeSciences Corporation (US), Smith+Nephew plc (UK), DSM-Firmenich (Netherlands), Nitta Gelatin Inc. (Japan), Tessenderlo Group (Belgium), Collplant Biotechnologies Ltd. (Israel)" Browse 280 market data Tables and 53 Figures spread through 252 Pages and in-depth TOC on "Collagen & Gelatin Market by Source (Bovine, Porcine, Marine), Application (Orthopedic, Cardiovascular, Dental, Surgical), Competitive Landscape (Company Profile, Market share, Company Evaluation Matrix), End User, and Region - Global Forecast to 2030 The global Collagen & Gelatin Market, valued at US$1,203.9 million in 2024, is forecasted to grow at a robust CAGR of 5.8%, reaching US$1,295.5 million in 2025 and an impressive US$1,671.3 million by 2030. Growing incidence of diabetes, cancer, and chronic diseases; rising demand for advanced wound care products; surge in surgical procedures; increasing use in tissue engineering and regenerative medicine; extensive application of collagen as a drug delivery system are driving the market. Browse in-depth TOC on " Collagen & Gelatin Market" 228 - Tables 44 - Figures 240 - Pages By Based on segment, the collagen & gelatin market is divided into bovine, porcine, and others. The large share of the bovine segment can be attributed to the growing adoption of bovine-derived collagen and gelatin in regenerative medicine. Additionally, the increased usage of biomaterials is primarily due to the biocompatibility and biodegradability properties exhibited by these materials. By Based on application, The collagen market is segmented into orthopaedic, wound care, dental, surgical, cardiovascular, and other applications. In 2024, the orthopaedic application segment accounted for the largest share of the collagen market by applications due to the rising demand for scaffolds and substitutes due to their extensive use in orthopaedic surgeries. This dominance is expected to continue throughout the forecast period due to the rising number of road trauma cases. By geography, the collagen & gelatin market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2024, North America held the largest share of the collagen & gelatin market, followed by Europe. Asia Pacific registered the highest CAGR growth within the collagen & gelatin market during the forecast period due to its increasing application for research and clinical diagnostics, adoption of collagen & gelatin for transplantation-associated research, and government initiatives and industrial collaboration. The report profiles key players such as Integra LifeSciences Corporation (US), Smith+Nephew plc (UK), DSM-Firmenich (Netherlands), Nitta Gelatin Inc. (Japan), Tessenderlo Group (Belgium), Collplant Biotechnologies Ltd. (Israel), Collagen Solutions plc (UK), Regenity (US), Medtronic plc (Ireland), and Solventum (US). INTEGRA LIFESCIENCES (US): Integra LifeSciences leads in the collagen & gelatin market. It operates through two business segments, namely Codman Specialty Surgical and Tissue Technologies. The company offers engineered bovine collagen, bovine dermis, porcine urinary bladder, human amniotic tissue, and resorbable synthetic mesh products through its Tissue Technologies Segment. This segment recorded a decline of 3.3% in 2024 over 2023 due to the impact of the lost revenue related to the Boston product recall, which was partially offset by double-digit growth from BioD and Gentrix and mid-single-digit growth in Integra skin and MediHoney. The company's leading position is attributable to its diversified product portfolio, geographical expansion, and adoption of organic and inorganic growth strategies. For instance, in March 2024, Integra Life Sciences received an US FDA approval to commercialize a dermal regeneration template for repairing scar contractures. SMITH+NEPHEW PLC (UK): Smith+Nephew is one of the leading players in the collagen & gelatin market due to its robust portfolio, including innovative collagen-based scaffolds and collagenase-based enzymatic debridement agents. The company operates through three business segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers collagen and gelatin products through its advanced wound management business segment. Additionally, the company's strong global presence, strategic partnerships, and commitment to customer-centric solutions position it as a key player in the competitive collagen and gelatin space. The company possesses a strong geographical presence with a broad range of distribution networks to solidify its leadership in the collagen and gelatin market. The advanced wound management business segment of Smith+Nephew has experienced a positive growth rate of 4.7% in the year 2024 and maintained positive momentum in 2024, with growth accelerating toward the end of the year. For more information, Inquire Now!
The Independent
22-05-2025
- Health
- The Independent
Widely used antidepressant could help the immune system fight cancer
A drug already taken by more than 8million people in the UK could help the immune system fight cancer and shrink tumours, a study finds. The widely used antidepressant - selective serotonin reuptake inhibitors, or SSRIs- is used to increase the availability of serotonin in the brain, a neurotransmitter that plays a role in mood, emotion and sleep. But scientists have also discovered the drug can enhance the ability of T cells, a type of white blood cell, to fight cancer and suppress tumour growth across a range of cancer types. The study published in the journal Cell by researchers at UCLA in California, looked at both mouse and human tumour models responsible for melanoma, breast, prostate, colon and bladder cancer. 'It turns out SSRIs don't just make our brains happier; they also make our T cells happier - even while they're fighting tumours,' said Dr Lili Yang, senior author of the new study and a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. 'These drugs have been widely and safely used to treat depression for decades, so repurposing them for cancer would be a lot easier than developing an entirely new therapy.' While serotonin is best known for the role it plays in the brain, it also plays a role in digestion, metabolism and immune activity. Dr Yang and her team first began investigating serotonin's role in fighting cancer after noticing that immune cells isolated from tumours had higher levels of serotonin-regulating molecules. At first, they focused on MAO-A, an enzyme that breaks down serotonin and other neurotransmitters, including norepinephrine and dopamine. In 2021, they reported that T cells produce MAO-A when they recognise tumours, which makes it harder for them to fight cancer. They found that treating mice with melanoma and colon cancer using MAO inhibitors, also called MAOIs - the first class of antidepressant drugs to be invented - helped T cells attack tumours more effectively. But because MAOIs can cause side-effects and interactions with certain foods, they decided to try a different serotonin-regulating molecule: SERT. 'Unlike MAO-A, which breaks down multiple neurotransmitters, SERT has one job - to transport serotonin,' explained Dr Bo Li, first author of the study and a senior research scientist in the Yang lab. 'SERT made for an especially attractive target because the drugs that act on it - SSRIs - are widely used with minimal side effects,' Dr Li said. The researchers tested SSRIs in mouse and human tumour models representing melanoma, breast, prostate, colon and bladder cancer and found they reduced tumour size by more than half. The antidepressant also made cancer-fighting T cells, known as killer T cells, more efficient. The team also tested the antidepressant alongside existing cancer therapies which work by suppressing immune cell activity to allow T cells to attack T cells more effectively. The combination reduced tumour size in all the treated mice. However, to confirm these findings the team will need to investigate whether real-world cancer patients taking SSRIs have better outcomes.
